Stifel Nicolaus & Co’s Esperion Therapeutics ESPR Stock Holding History

Stifel Nicolaus & Co’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	$427K	Buy	+22,627	New	+$380K	0.01%	972

Other funds holding ESPR

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

MCM

Mazama Capital Management Portland, Oregon $544M AUM 9.52% 1-Year Est. Return

Stifel Nicolaus & Co's ESPR Position: Q3 2013 in Review

Stifel Nicolaus & Co opened a new position in Esperion Therapeutics (ESPR) in Q3 2013: 22,627 shares worth $427K. The stake represents 0.01% of the portfolio and ranks #972 among its holdings.

44 funds tracked by Wall St. Rank hold ESPR as of Q3 2013.

Stifel Nicolaus & Co held 22,627 shares of Esperion Therapeutics worth $427K as of Q3 2013.
Esperion Therapeutics was a new Stifel Nicolaus & Co position in Q3 2013.
Esperion Therapeutics made up 0.01% of Stifel Nicolaus & Co's portfolio in Q3 2013, its #972 holding.
44 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2013.

Based on Stifel Nicolaus & Co's 13F filing for Q3 2013, filed 13 Nov 2013.